

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	290	echinocandin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:32			0
2	BRS	L3	28828	antifungal	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:32			0
3	BRS	L4	13	2 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:33			0
4	BRS	L5	5159	anti-fungal	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:33			0
5	BRS	L6	4	2 same 5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:37			0
6	BRS	L7	1	wo-9613272-\$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 09:37			0
7	BRS	L2	24	echinocandin adj derivative	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:07			0
8	BRS	L8	166	1 same (3 or 5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:36			0
9	BRS	L9	36	fauveau adj patrick.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:37			0
10	BRS	L10	4	hawser adj stephen.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:38			0
11	BRS	L11	0	lebourg adj gilles.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:39			0
12	BRS	L12	9	schio adj laurent.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:39			0
13	BRS	L13	4	(9 or 10 or 12) and 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/03 10:40			0

=> d his

(FILE 'HOME' ENTERED AT 15:19:38 ON 03 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'  
ENTERED AT

15:20:04 ON 03 SEP 2003

L1 1691 S ECHINOCANDIN  
L2 379 S L1 (P) DERIVATIVE  
L3 115 S ECHINOCANDIN DERIVATIVE  
L4 121417 S ANTI-FUNGAL OR ANTIFUNGAL  
L5 159 S (L2 OR L3 ) (P) L4  
L6 72 DUPLICATE REMOVE L5 (87 DUPLICATES REMOVED)  
L7 18 S FAUVEAU PATRICK/AU  
L8 15 S HAWSER STEPHEN/AU  
L9 1 S LEBOURG GILLES/AU  
L10 22 S SCHIO LAURENT/AU  
L11 5 S (L10 OR L7 OR L8 OR L9) AND L6

the STN search turned up 36 cpds in 2 citations  
only 18 cpds were in the 2 cites. these are the

KAM 10/018,073

=> d 145 1-18

L45 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN

RN 310462-00-1 REGISTRY

CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C63 H83 N9 O14


CI COM

SR CA


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Registry records for the remaining 18. The Reg # are really high - so these must be pretty new & not yet assigned to a citation.

PAGE 1-A




PAGE 2-A



KAM 10/018,073


PAGE 3-A




L45 ANSWER 2 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 310461-98-4 REGISTRY  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C63 H83 N9 O14  
CI COM  
SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A



PAGE 3-A





L45 ANSWER 3 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310461-96-2 REGISTRY  
 CN Deoxymulundocandin, 1-[(4S)-4-[(1H-benzimidazol-1-ylmethyl)amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C65 H78 N10 O14  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A







L45 ANSWER 4 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310461-94-0 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[(1H-benzimidazol-1-ylmethyl)amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C65 H78 N10 O14  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


Absolute stereochemistry.






L45 ANSWER 5 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310461-88-2 REGISTRY  
 CN Deoxymulundocandin, 1-[[4S]-4-[[[(2S)-2-aminopropyl]amino]-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C57 H81 N9 O14  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*




PAGE 2-A




L45 ANSWER 6 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310461-85-9 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(2S)-2-aminopropyl]amino]-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C57 H81 N9 O14  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

PAGE 1-A



PAGE 2-A




KAM 10/018,073


L45 ANSWER 7 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 310459-69-9 REGISTRY  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]- (9CI)  
(CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C59 H79 N11 O14 S  
CI COM  
SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 8 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-66-6 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]]-L-ornithine]- (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C59 H79 N11 O14 S  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 9 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-60-0 REGISTRY  
 CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]- (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C59 H79 N11 O14 S  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 10 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-57-5 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]- (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C59 H79 N11 O14 S  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 11 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-41-7 REGISTRY  
 CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[3-[4-(pentyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-L-ornithine]- (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C59 H79 N11 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 12 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-38-2 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[3-[4-(pentyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-L-ornithine]- (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C59 H79 N11 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A



PAGE 3-A




L45 ANSWER 13 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-35-9 REGISTRY  
 CN Deoxymulundocandin, 1-[[4S)-4-[[[(2S)-2-aminopropyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C57 H76 N10 O15  
 CI COM  
 SR CA


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L45 ANSWER 14 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-32-6 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(2S)-2-aminopropyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C57 H76 N10 O15  
 CI COM  
 SR CA


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




L45 ANSWER 15 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-29-1 REGISTRY  
 CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C60 H80 N10 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 16 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-26-8 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazoly]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C60 H80 N10 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 17 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-22-4 REGISTRY  
 CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C60 H80 N10 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A




PAGE 3-A




L45 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 310459-19-9 REGISTRY  
 CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C60 H80 N10 O15  
 CI COM  
 SR CA

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


PAGE 1-A



PAGE 2-A



PAGE 3-A



# Inventu Search

KAM 10/018,073

=> d que 110

L7 1 SEA FILE=CAPLUS ABB=ON PLU=ON WO 2000-FR1568/AP *PCT*  
 L8 20 SEA FILE=REGISTRY ABB=ON PLU=ON (138626-63-8/BI OR 160430-95-5/BI OR 19777-66-3/BI OR 20439-47-8/BI OR 227472-53-9/BI OR 227472-54-0/BI OR 227472-55-1/BI OR 227472-60-8/BI OR 310461-86-0/BI OR 310461-89-3/BI OR 310461-95-1/BI OR 310461-97-3/BI OR 310461-99-5/BI OR 310462-01-2/BI OR 340020-20-4/BI OR 538-75-0/BI OR 5805-57-2/BI OR 59748-18-4/BI OR 771-61-9/BI OR 9027-19-4/BI)

L9 12 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND "DEOXYMULUNDOCANDIN" *12 cpds w/ claimed*  
 L10 1 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND L9 *1 cite ring str*

=> d ibib abs hitstr ind 110

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:881186 CAPLUS

DOCUMENT NUMBER: 134:17731

TITLE: Echinocandin derivatives, method for preparing same and application as glucan synthase inhibitors and antifungal agents

INVENTOR(S): Fauveau, Patrick; Hawser, Stephen; Lebourg, Gilles; Schio, Laurent

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

*PCT document  
Parent case*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075177	A1	20001214	WO 2000-FR1568	20000608 <--
W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2794746	A1	20001215	FR 1999-7251	19990609
FR 2794746	B1	20021206		
EP 1189933	A1	20020327	EP 2000-942169	20000608
EP 1189933	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003501441	T2	20030114	JP 2001-502458	20000608
AT 236928	E	20030415	AT 2000-942169	20000608
PRIORITY APPLN. INFO.:			FR 1999-7251	A 19990609
			WO 2000-FR1568	W 20000608
OTHER SOURCE(S):		CASREACT 134:17731; MARPAT 134:17731		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention concerns in all possible isomeric forms as well as their mixts., cyclic peptides I wherein: R represents a linear, branched or cyclic chain; either R1 represents H or CH3 and R2 represents cyclohexyl substituted by an amine, cyanoalkyl; or R1 and R2 form with the nitrogen which bears them a cycle with 3, 4 or 5 carbons optionally substituted by an amine; R3 represents hydrogen, Me or hydroxyl; R4 represents hydrogen or hydroxyl; T represents hydrogen, Me, CH2CONH2, CH2CN, a (CH2)2NH2 or (CH2)2Nalk+X- radical, X being halogen and alk an alkyl radical; Y

KAM 10/018,073

represents hydrogen, hydroxyl, halogen or OSO<sub>3</sub>H; W represents H or OH; Z represents H, CH<sub>3</sub>. The compds. of formula I have antifungal properties. Thus, Trans 1-[4-[(2-aminocyclohexyl)amino]-N<sub>2</sub>-[[4'-(pentyloxy)[1,1':4',1''terphenyl]-4-yl]carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate was prepd. and tested for its inhibition of glucan synthase of *Candida albicans* and of the enzyme prepd. from *Aspergillus fumigatus*.

IT 310461-86-0P 310461-89-3P 310461-95-1P

310461-97-3P 310461-99-5P 310462-01-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

RN 310461-86-0 CAPLUS


CN Deoxymulundocandin, 1-[(4R)-4-[[[(2S)-2-aminopropyl]amino]-N<sub>2</sub>-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310461-85-9

CMF C57 H81 N9 014

PAGE 1-A




PAGE 2-A



CM 2

KAM 10/018,073

CRN 76-05-1  
CMF C2 H F3 O2




RN 310461-89-3 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(2S)-2-aminopropyl]amino]-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310461-88-2  
CMF C57 H81 N9 O14

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1

KAM 10/018,073

CMF C2 H F3 O2




RN 310461-95-1 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[(1H-benzimidazol-2-ylmethyl)amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310461-94-0  
CMF C65 H78 N10 O14

Absolute stereochemistry.

PAGE 1-A




*this could be #1 in  
claim 15  
or  
next page*



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310461-97-3 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[(1H-benzimidazol-2-ylmethyl)amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310461-96-2  
CMF C65 H78 N10 O14

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



this could be #1 in  
claim 15  
I don't know  
if isomer B is  
the R or S

CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 310461-99-5 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-,


KAM 10/018,073

trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310461-98-4  
CMF C63 H83 N9 O14


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073




RN 310462-01-2 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310462-00-1  
CMF C63 H83 N9 O14


PAGE 1-A



# 2 claim 15


PAGE 2-A






CM 2

CRN 76-05-1  
CMF C2 H F3 O2




IT 138626-63-8, Deoxymulundocandin 227472-60-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(echinocandin derivs., method for prepg. same and application as glucan  
synthase inhibitors and antifungal agents)  
RN 138626-63-8 CAPLUS  
CN Deoxymulundocandin (9CI) (CA INDEX NAME)




RN 227472-60-8 CAPLUS  
CN Deoxymulundocandin, 1-[(4R,5R)-4,5-dihydroxy-N2-[[4''-(  
pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA  
INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 227472-53-9P 227472-54-0P 227472-55-1P  
340020-20-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(echinocandin derivs., method for prepg. same and application as glucan  
synthase inhibitors and antifungal agents)


RN 227472-53-9 CAPLUS

CN Deoxymulundocandin, 1-[(4R,5R)-4,5-dihydroxy-L-ornithine]- (9CI) (CA  
INDEX NAME)




RN 227472-54-0 CAPLUS  
 CN Deoxymulundocandin, 1-[(4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




KAM 10/018,073

RN 227472-55-1 CAPLUS  
CN Deoxymulundocandin, 1-[N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-4-oxo-L-ornithine]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 340020-20-4 CAPLUS  
CN Deoxymulundocandin, 1-[4-oxo-N2-[[4'-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IC ICM C07K007-56  
 ICS A61K038-12; A61P031-10  
 CC 34-3 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 7, 10, 63  
 ST echinocandin cyclic peptide prepn antifungal glucan synthase inhibitor  
 IT Peptides, preparation  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (cyclic; echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)  
 IT Aspergillus fumigatus  
 Fungicides  
 (echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)  
 IT 9027-19-4, Glucan synthase  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)  
 (Candida albicans; echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

IT 310461-86-OP 310461-89-3P 310461-95-1P  
 310461-97-3P 310461-99-5P 310462-01-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

IT 538-75-0, N,N'-Dicyclohexylcarbodiimide 771-61-9, 2,3,4,5,6-Pentafluorophenol 5805-57-2, 2-(Aminomethyl)benzimidazole 19777-66-3  
 20439-47-8 59748-18-4 138626-63-8, Deoxymulundocandin 227472-60-8  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

IT 160430-95-5P 227472-53-9P 227472-54-OP  
 227472-55-1P 340020-20-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



KAM 10/018,073

VAR G2=67/68/77/88/83/80/96/100  
VAR G3=70/72/73/74/75/76/90  
REP G4=(0-7) CH2  
VAR G5=CN/OH  
VAR G6=116/67/108

NODE ATTRIBUTES:

NSPEC IS R AT 67  
CONNECT IS E1 RC AT 103  
DEFAULT MLEVEL IS ATOM  
GGCAT IS PCY UNS AT 70  
GGCAT IS MCY UNS AT 72  
GGCAT IS PCY UNS AT 73  
GGCAT IS MCY UNS AT 74  
GGCAT IS MCY UNS AT 75  
GGCAT IS MCY UNS AT 76  
GGCAT IS MCY UNS AT 81  
GGCAT IS MCY SAT AT 88  
GGCAT IS LIN SAT AT 96  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS E7 C E2 N AT 70  
ECOUNT IS E4 C E1 N AT 72  
ECOUNT IS E8 C E1 N AT 73  
ECOUNT IS E3 C E2 N AT 74  
ECOUNT IS E4 C E1 O AT 75  
ECOUNT IS E5 C E1 N AT 76  
ECOUNT IS E6 C AT 81  
ECOUNT IS E6 C AT 88  
ECOUNT IS E2 C AT 96

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE

L37 36 SEA FILE=REGISTRY SUB=L16 SSS FUL L36 36 cpds  
L38 2 SEA FILE=CAPLUS ABB=ON PLU=ON L37 2 ci + es

=> d ibib abs hitstr 138 1

L38 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:881187 CAPLUS

DOCUMENT NUMBER: 134:17732

TITLE: Novel echinocandin derivatives, method for preparing same and use as antifungal agents

INVENTOR(S): Corbier, Alain; Fauveau, Patrick; Pietre-Dischamp, Nathalie; Schio, Laurent; Vicat, Pascale

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075178	A1	20001214	WO 2000-FR1569	20000608
W:				
AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2794747	A1	20001215	FR 1999-7252	19990609
EP 1189932	A1	20020327	EP 2000-940456	20000608

KAM 10/018,073

EP 1189932 B1 20030521  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
JP 2003504309 T2 20030204 JP 2001-502459 20000608  
AT 240971 E 20030615 AT 2000-940456 20000608  
PRIORITY APPLN. INFO.: FR 1999-7252 A 19990609  
WO 2000-FR1569 W 20000608  
OTHER SOURCE(S): CASREACT 134:17732; MARPAT 134:17732  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention concerns cyclic peptides I wherein: R = chain contg. up to 30 carbon atoms, optionally contg. one or several heteroatoms, one or several heterocycles; either R1 and R2 = H, OH, alkyl optionally substituted, or NR1 forms with the carbon bearing NR1R2 a double bond and R2 is XRa, X being O, NH or N-alkyl and Ra being H, alkyl optionally substituted; R3 = H, OH, CH3; R4 = H, OH; T = H, CH3, CH2CONH2, CH2CN, (CH2)2NH2; Y = H, OH, halogen, OSO3H; W = H, OH; Z = H or CH3. The products of formula I have antifungal properties. Thus, trans-1-[4-[(2-aminocyclo-hexyl)amino]-N2-[[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]phenyl]carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B trifluoroacetate was prepd. and tested for its inhibition of glucan synthase of Candida albicans.


IT 310459-20-2P 310459-23-5P 310459-27-9P  
310459-30-4P 310459-33-7P 310459-36-0P  
310459-39-3P 310459-42-8P 310459-58-6P  
310459-61-1P 310459-67-7P 310459-70-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(novel echinocandin derivs. method for prepg. same and use as glucan synthase inhibitors and antifungal agents)

RN 310459-20-2 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-19-9  
CMF C60 H80 N10 O15


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073




RN 310459-23-5 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1


CRN 310459-22-4  
CMF C60 H80 N10 O15

PAGE 1-A




PAGE 2-A





CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 310459-27-9 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-26-8  
CMF C60 H80 N10 O15




KAM 10/018,073

PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310459-30-4 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-29-1  
CMF C60 H80 N10 O15


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073



RN 310459-33-7 CAPLUS

CN Deoxymulundocandin, 1-[(4R)-4-[[[(2S)-2-aminopropyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-32-6


CMF C57 H76 N10 O15

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

KAM 10/018,073

CRN 76-05-1  
CMF C2 H F3 O2




RN 310459-36-0 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(2S)-2-aminopropyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-35-9  
CMF C57 H76 N10 O15

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 310459-39-3 CAPLUS

CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[3-[4-(pentyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310459-38-2

CMF C59 H79 N11 O15




KAM 10/018,073

PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310459-42-8 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[3-[4-(pentyloxy)phenyl]-1,2,4-oxadiazol-5-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-41-7  
CMF C59 H79 N11 O15


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073




RN 310459-58-6 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310459-57-5


CMF C59 H79 N11 O14 S

PAGE 1-A




PAGE 2-A





CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 310459-61-1 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1S,2S)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-60-0  
CMF C59 H79 N11 O14 S




KAM 10/018,073

PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310459-67-7 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310459-66-6  
CMF C59 H79 N11 O14 S


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073




RN 310459-70-2 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310459-69-9


CMF C59 H79 N11 O14 S

PAGE 1-A




PAGE 2-A





CM 2

CRN 76-05-1  
CMF C2 H F3 O2

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 138 2

L38 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:881186 CAPLUS

DOCUMENT NUMBER: 134:17731

TITLE: Echinocandin derivatives, method for preparing same  
and application as glucan synthase inhibitors and  
antifungal agentsINVENTOR(S): Fauveau, Patrick; Hawser, Stephen; Lebourg, Gilles;  
Schio, Laurent

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

*Same citation as  
the inventor  
search*

*CPDs are printed  
out to confirm  
that the search  
picked up all of  
the STR'S in the  
inventor search*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075177	A1	20001214	WO 2000-FR1568	20000608
W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2794746	A1	20001215	FR 1999-7251	19990609
FR 2794746	B1	20021206		
EP 1189933	A1	20020327	EP 2000-942169	20000608
EP 1189933	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003501441	T2	20030114	JP 2001-502458	20000608
AT 236928	E	20030415	AT 2000-942169	20000608
PRIORITY APPLN. INFO.:			FR 1999-7251 A 19990609	
			WO 2000-FR1568 W 20000608	
OTHER SOURCE(S):			CASREACT 134:17731; MARPAT 134:17731	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention concerns in all possible isomeric forms as well as their mixts., cyclic peptides I wherein: R represents a linear, branched or cyclic chain; either R1 represents H or CH3 and R2 represents cyclohexyl substituted by an amine, cyanoalkyl ; or R1 and R2 form with the nitrogen which bears them a cycle with 3, 4 or 5 carbons optionally substituted by an amine; R3 represents hydrogen, Me or hydroxyl; R4 represents hydrogen or hydroxyl; T represents hydrogen, Me, CH2CONH2, CH2CN, a (CH2)2NH2 or (CH2)2Nalk+X- radical, X being halogen and alk an alkyl radical; Y represents hydrogen, hydroxyl, halogen or OSO3H; W represents H or OH; Z represents H, CH3. The compds. of formula I have antifungal properties. Thus, . Trans 1-[4-[(2-aminocyclohexyl)amino]-N2-[[4'-(pentyloxy)[1,1':4',1''terphenyl]-4-yl]carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate was prepd. and tested for its inhibition of glucan synthase of *Candida albicans* and of the enzyme prepd. from *Aspergillus fumigatus*.

IT 310461-86-0P 310461-89-3P 310461-95-1P  
310461-97-3P 310461-99-5P 310462-01-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(echinocandin derivs., method for prepg. same and application as glucan synthase inhibitors and antifungal agents)

RN 310461-86-0 CAPLUS


CN Deoxymulundocandin, 1-[(4R)-4-[[[(2S)-2-aminopropyl]amino]-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310461-85-9

CMF C57 H81 N9 O14

PAGE 1-A






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 310461-89-3 CAPLUS

CN Deoxymulundocandin, 1-[(4S)-4-[[[(2S)-2-aminopropyl]amino]-N2-[[4'-(octyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310461-88-2

CMF C57 H81 N9 O14




PAGE 2-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310461-95-1 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[(1H-benzimidazol-2-ylmethyl)amino]-N2-[[4'-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 310461-94-0  
CMF C65 H78 N10 O14


Absolute stereochemistry.

PAGE 1-A




KAM 10/018,073

PAGE 2-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 310461-97-3 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[(1H-benzimidazol-2-ylmethyl)amino]-N2-[[4'-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 310461-96-2  
CMF C65 H78 N10 O14

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 310461-99-5 CAPLUS  
CN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-,


KAM 10/018,073

trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310461-98-4  
CMF C63 H83 N9 O14


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

KAM 10/018,073




RN 310462-01-2 CAPLUS  
CN Deoxymulundocandin, 1-[(4S)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[[4'-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 310462-00-1  
CMF C63 H83 N9 O14

PAGE 1-A




PAGE 2-A




KAM 10/018,073

PAGE 3-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT